Coronary Functional Abnormalities in Patients With Angina and Nonobstructive Coronary Artery Disease.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
12 11 2019
Historique:
received: 15 04 2019
revised: 20 08 2019
accepted: 26 08 2019
entrez: 9 11 2019
pubmed: 9 11 2019
medline: 23 5 2020
Statut: ppublish

Résumé

Approximately one-half of patients undergoing diagnostic coronary angiography for angina have no significant coronary stenosis, in whom coronary functional abnormalities could be involved. This study examined the significance of coronary functional abnormalities in a comprehensive manner for both epicardial and microvascular coronary arteries in patients with angina and nonobstructive coronary artery disease (CAD). This study prospectively enrolled 187 consecutive patients (male/female 113/74, 63.2 ± 12.3 years), who underwent acetylcholine provocation test for coronary spasm and measurement of index of microcirculatory resistance (IMR) to evaluate coronary microvascular function, and followed them for a median of 893 days. Of all subjects, acetylcholine test identified 128 patients with vasospastic angina (VSA) (68%), and cardiac events occurred in 10 patients (5.3%) during the follow-up. Multivariable analysis revealed that IMR correlated with the incidence of cardiac events (hazard ratio: 1.05; 95% confidence interval: 1.02 to 1.09; p = 0.002) and receiver-operating characteristics (ROC) curve analysis identified IMR of 18.0 as the optimal cut-off value. Among the 4 groups based on the cut-off value of IMR and the presence of VSA, the Kaplan-Meier survival analysis showed a significantly worse prognosis in the group with high IMR (≥18.0) and VSA compared with other groups (log rank, p = 0.002). Importantly, intracoronary administration of fasudil, a Rho-kinase inhibitor, significantly ameliorated IMR in the VSA patients with increased IMR (p < 0.0001). These results indicate that in patients with angina and nonobstructive CAD, coexistence of epicardial coronary spasm and increased microvascular resistance is associated with worse prognosis, for which Rho-kinase activation may be involved.

Sections du résumé

BACKGROUND
Approximately one-half of patients undergoing diagnostic coronary angiography for angina have no significant coronary stenosis, in whom coronary functional abnormalities could be involved.
OBJECTIVES
This study examined the significance of coronary functional abnormalities in a comprehensive manner for both epicardial and microvascular coronary arteries in patients with angina and nonobstructive coronary artery disease (CAD).
METHODS
This study prospectively enrolled 187 consecutive patients (male/female 113/74, 63.2 ± 12.3 years), who underwent acetylcholine provocation test for coronary spasm and measurement of index of microcirculatory resistance (IMR) to evaluate coronary microvascular function, and followed them for a median of 893 days.
RESULTS
Of all subjects, acetylcholine test identified 128 patients with vasospastic angina (VSA) (68%), and cardiac events occurred in 10 patients (5.3%) during the follow-up. Multivariable analysis revealed that IMR correlated with the incidence of cardiac events (hazard ratio: 1.05; 95% confidence interval: 1.02 to 1.09; p = 0.002) and receiver-operating characteristics (ROC) curve analysis identified IMR of 18.0 as the optimal cut-off value. Among the 4 groups based on the cut-off value of IMR and the presence of VSA, the Kaplan-Meier survival analysis showed a significantly worse prognosis in the group with high IMR (≥18.0) and VSA compared with other groups (log rank, p = 0.002). Importantly, intracoronary administration of fasudil, a Rho-kinase inhibitor, significantly ameliorated IMR in the VSA patients with increased IMR (p < 0.0001).
CONCLUSIONS
These results indicate that in patients with angina and nonobstructive CAD, coexistence of epicardial coronary spasm and increased microvascular resistance is associated with worse prognosis, for which Rho-kinase activation may be involved.

Identifiants

pubmed: 31699275
pii: S0735-1097(19)37681-8
doi: 10.1016/j.jacc.2019.08.1056
pii:
doi:

Substances chimiques

Protein Kinase Inhibitors 0
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine 84477-87-2
rho-Associated Kinases EC 2.7.11.1
fasudil Q0CH43PGXS

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2350-2360

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Akira Suda (A)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Jun Takahashi (J)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Kiyotaka Hao (K)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Yoku Kikuchi (Y)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Tomohiko Shindo (T)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Shohei Ikeda (S)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Koichi Sato (K)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Jun Sugisawa (J)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Yasuharu Matsumoto (Y)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Satoshi Miyata (S)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Yasuhiko Sakata (Y)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Hiroaki Shimokawa (H)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: shimo@cardio.med.tohoku.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH